Made an agreement with Knop Laboratories: Zelda Therapeutics Ltd (ASX: ZLD) made a manufacturing and distribution agreement with Knop Laboratories. As a result, the stock rallied over 86.8% in this year to date (as of July 7th, 2017). With this move, the group would be able to fasten their clinical trial process, as there is already a certainty of product supply. This would also enable the mass production of the group’s medicines for the treatment of eczema, insomnia and autism, offering a natural alternative to many patients who suffer from these conditions. Knop is well positioned in Chile with a chain of pharmacies and there is a possibility for them to be a major distribution channel for Zelda registered medicines post their finishing of the clinical trials in insomnia, eczema and the recently announced expansion into autism. The group chose Chile for their research work as the region legal framework recognizes the importance of medical cannabis, while enables their production under strict regulatory controls for the treatment of medical conditions. The country is also a cost-effective destination for Zelda to conduct clinical trials.